Drug Trial Radar · NCT06079671
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Sep 22, 2023
Primary completion
Nov 26, 2027
Study completion Sep 30, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Gynecologic Oncology Group Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT)
- First posted
- Oct 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.
Conditions
- Locally Advanced Cervical Cancer
Interventions
VolrustomigBiological
IV Infusion
PlaceboOther
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) based on the investigator assessment in all randomized participants (FAS)Time frame: Up to approximately 7 years
Locations
205 sites in 19 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama · Withdrawn
Research Site
Phoenix, Arizona · Withdrawn
Research Site
Tucson, Arizona · Withdrawn
Research Site
Little Rock, Arkansas · Withdrawn
Research Site
La Jolla, California · Withdrawn
Research Site
West Hollywood, California · Withdrawn
Research Site
Atlanta, Georgia · Withdrawn
Research Site
Augusta, Georgia · Withdrawn
Research Site
Savannah, Georgia · Terminated
Research Site
Melrose Park, Illinois · Withdrawn
Research Site
Indianapolis, Indiana · Withdrawn
Research Site
New Orleans, Louisiana · Withdrawn
Research Site
New Orleans, Louisiana · Withdrawn
Research Site
Shreveport, Louisiana · Completed
Research Site
New York, New York · Withdrawn
Research Site
Syracuse, New York · Withdrawn
Research Site
Cleveland, Ohio · Withdrawn
Research Site
Columbus, Ohio · Withdrawn
Research Site
Eugene, Oregon · Withdrawn
Research Site
Philadelphia, Pennsylvania · Withdrawn
Research Site
Providence, Rhode Island · Withdrawn
Research Site
Dallas, Texas · Withdrawn
Research Site
Fort Worth, Texas · Terminated
Research Site
Houston, Texas · Withdrawn
Research Site
Tyler, Texas · Withdrawn
Research Site
Charlottesville, Virginia · Completed
Research Site
Fairfax, Virginia · Withdrawn
Research Site
Richmond, Virginia · Withdrawn
Research Site
Barretos, Brazil · Recruiting
Research Site
Belo Horizonte, Brazil · Recruiting
Research Site
Curitiba, Brazil · Recruiting
Research Site
Fortaleza, Brazil · Recruiting
Research Site
Fortaleza, Brazil · Recruiting
Research Site
Goiânia, Brazil · Not yet recruiting
Research Site
Ijuí, Brazil · Recruiting
Research Site
Natal, Brazil · Recruiting
Research Site
Porto Alegre, Brazil · Recruiting
Research Site
Porto Alegre, Brazil · Recruiting
Research Site
Porto Alegre, Brazil · Recruiting
Research Site
Porto Velho, Brazil · Recruiting
Showing 40 of 205 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.